MOLECULAR PHARMACOLOGY

Scope & Guideline

Unlocking Molecular Mechanisms for Better Therapeutics

Introduction

Welcome to your portal for understanding MOLECULAR PHARMACOLOGY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0026-895x
PublisherAMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1965 to 2024
AbbreviationMOL PHARMACOL / Mol. Pharmacol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995

Aims and Scopes

Molecular Pharmacology focuses on the intricate relationship between molecular mechanisms and pharmacological interventions, providing a platform for research that bridges basic science and clinical applications. The journal encompasses a broad spectrum of studies aimed at elucidating the pathways involved in drug action, disease progression, and therapeutic strategies.
  1. Pharmacological Mechanisms:
    Research exploring the molecular mechanisms of drug action, including receptor interactions, signaling pathways, and pharmacodynamics, is central to the journal's scope.
  2. Disease Mechanisms:
    Papers that investigate the molecular basis of diseases, particularly cancer, cardiovascular disorders, and neurodegenerative diseases, contribute to understanding how pharmacological interventions can be optimized.
  3. Therapeutic Innovations:
    The journal emphasizes innovative therapeutic strategies and drug development, including the use of natural products, nanomedicine, and novel pharmacological agents.
  4. Translational Research:
    A significant focus on translational research that bridges laboratory findings with clinical applications, aiming to enhance therapeutic outcomes in various diseases.
  5. Interdisciplinary Approaches:
    Encouragement of interdisciplinary research that integrates molecular biology, pharmacology, and clinical medicine to tackle complex health issues.
Molecular Pharmacology is adapting to new scientific advancements and societal health challenges, with emerging themes reflecting contemporary research priorities and innovative therapeutic approaches.
  1. Cancer Pharmacology:
    An increased focus on cancer pharmacology, particularly studies involving targeted therapies, immunotherapies, and the molecular mechanisms underlying tumor progression and resistance.
  2. Neuropharmacology:
    Growing interest in neuropharmacology, with research exploring the molecular underpinnings of neurodegenerative diseases and the potential of novel neuroprotective agents.
  3. Natural Products and Herbal Medicine:
    A resurgence in the exploration of natural products as therapeutic agents, emphasizing their molecular mechanisms and potential in modern pharmacotherapy.
  4. Nanomedicine:
    Emerging studies focusing on nanocarriers and nanotechnology applications in drug delivery systems, highlighting their role in enhancing drug efficacy and targeting.
  5. MicroRNA and Epigenetics:
    A trend towards understanding the roles of microRNAs and epigenetic modifications in disease processes and their potential as therapeutic targets.

Declining or Waning

While Molecular Pharmacology has consistently addressed a wide array of topics, certain areas have seen a decline in publication frequency, suggesting shifts in research focus or emerging priorities within the field.
  1. Traditional Pharmacology:
    There appears to be a waning emphasis on traditional pharmacological studies, particularly those focusing solely on classical drug action mechanisms without integrating modern molecular insights.
  2. Single-agent Studies:
    Research centered around single-agent therapies is declining, as there is a growing trend towards combination therapies and polypharmacology.
  3. Animal Models:
    Papers relying heavily on animal models without translational relevance are becoming less common, reflecting a shift towards more human-relevant research methodologies.
  4. Basic Biochemical Studies:
    While foundational studies remain important, there is a noticeable decrease in purely biochemical investigations that do not connect to broader physiological or clinical implications.
  5. Focus on Non-Cancer Diseases:
    Areas related to non-cancer diseases, although still relevant, have seen less representation compared to the overwhelming focus on oncology-related pharmacology.

Similar Journals

JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION

Connecting Science through Receptor and Signaling Studies
Publisher: TAYLOR & FRANCIS LTDISSN: 1079-9893Frequency: 6 issues/year

JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, published by TAYLOR & FRANCIS LTD, is a premier academic journal dedicated to advancing our understanding of receptor biology and signal transduction mechanisms. With an ISSN of 1079-9893 and an E-ISSN of 1532-4281, this journal has maintained a reputable standing since its inception in 1980, continually addressing pivotal topics in biochemistry, cell biology, and molecular biology. As evidenced by its 2023 Scopus rankings, which place it in the 64th percentile for Biochemistry and Genetics and Molecular Biology, JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION remains a vital source for cutting-edge research, providing insights that are essential for both academic and practical applications. Although the journal currently offers limited open access options, it stands out in the Q2 and Q3 quartiles of its respective categories, making it an invaluable resource for researchers, professionals, and students aiming to stay abreast of the latest findings and methodologies in receptor and signaling research. The journal's commitment to disseminating high-quality research underscores its significance within the scientific community, fostering innovation and collaboration across disciplines.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Unveiling Innovations in Drug Action and Therapeutics
Publisher: SPRINGERISSN: 0028-1298Frequency: 12 issues/year

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is a prestigious journal published by SPRINGER, focusing on the dynamic fields of pharmacology and toxicology. With an ISSN of 0028-1298 and an E-ISSN of 1432-1912, this esteemed publication has been a staple in the scientific community since its inception in 1969, continuing to wield influence with a convergence of research that reaches through 2024. Ranked in the Q2 category for both medicine and pharmacology, it stands at an impressive 111th out of 313 in the Scopus rankings for pharmacology, reflecting its significant impact in the field. Though not offering open access, the journal remains a vital resource for researchers, professionals, and students seeking to explore groundbreaking studies and advancements in pharmacological science. With its high standards and comprehensive coverage, NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is essential reading for those dedicated to understanding the mechanisms of drug action and the complexities of therapeutic interventions.

NEUROPHARMACOLOGY

Charting New Territories in Neuropharmacological Science
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0028-3908Frequency: 16 issues/year

NEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.

Bangladesh Journal of Pharmacology

Advancing Pharmacological Knowledge for a Healthier Tomorrow
Publisher: BANGLADESH PHARMACOLOGICAL SOCISSN: 1991-007XFrequency: 4 issues/year

The Bangladesh Journal of Pharmacology, published by the Bangladesh Pharmacological Society, is a leading platform dedicated to advancing knowledge in the field of pharmacology. With an ISSN of 1991-007X and an E-ISSN of 1991-0088, this open access journal has been making significant contributions to the field since its inception in 2006. Located at the Bangabandhu Sheikh Mujib Medical University in Dhaka, Bangladesh, the journal provides a vital resource for researchers, professionals, and students interested in pharmacology, toxicology, and pharmaceutics. As of 2023, the journal is categorized in the Q4 quartile for pharmacology, ranking 240th out of 313 in Scopus and falling within the 23rd percentile, reflecting its commitment to the dissemination of high-quality research. The journal encompasses a diverse array of topics from basic research to clinical applications, aiming to foster a deeper understanding of pharmacological principles and practices. By providing open access to its content, the Bangladesh Journal of Pharmacology ensures that valuable scientific findings are readily available to the global community, supporting the advancement of medical and pharmaceutical sciences.

BIOLOGICAL & PHARMACEUTICAL BULLETIN

Fostering Excellence in Biomedical and Pharmaceutical Discourse
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0918-6158Frequency: 12 issues/year

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

Biomolecules & Therapeutics

Elevating Research Standards in Biomolecular Science
Publisher: KOREAN SOC APPLIED PHARMACOLOGYISSN: 1976-9148Frequency: 4 issues/year

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

ACS Pharmacology & Translational Science

Driving breakthroughs from bench to bedside.
Publisher: AMER CHEMICAL SOCISSN: Frequency: 12 issues/year

ACS Pharmacology & Translational Science is a premier journal published by the American Chemical Society, dedicated to advancing knowledge in the fields of pharmacology and translational science. Operating since 2018, the journal has quickly established itself as a leader in its domain, holding a prestigious Q1 ranking in both Pharmacology and Medical Pharmacology for 2023. With a robust Scopus ranking, it currently occupies the 21st position out of 272 in Medical Pharmacology, reflecting its significant impact within the scientific community at the 92nd percentile. The journal provides an open-access platform for researchers to disseminate innovative findings and viewpoints that bridge the gap between drug discovery and clinical application. In an era where translational research is critical for the success of pharmacological advances, ACS Pharmacology & Translational Science serves as an essential resource for scientists, professionals, and students eager to explore cutting-edge developments in drug development and therapeutic strategies. The journal is based in the United States, with a commitment to fostering collaboration and knowledge sharing across borders.

Physiology and Pharmacology

Disseminating high-quality research for a healthier future.
Publisher: IRANIAN SOC PHYSIOLOGY & PHARMACOLOGYISSN: 2476-5236Frequency: 4 issues/year

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Unveiling Cutting-Edge Developments in Drug and Body Dynamics
Publisher: WILEYISSN: 0305-1870Frequency: 12 issues/year

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.

MEDICINAL RESEARCH REVIEWS

Transforming Research into Revolutionary Therapeutics
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.